Table 4 Key efficacy outcomes
Efficacy outcome | Safety population (n = 80) | Treatment cohort (n = 41) |
|---|---|---|
Duration of response, months | 18.4 (11.9–29.6) | 35.1 (25.5–38.2) |
Time to progression, months | 13.8 (11.2–20.4) | 36.9 (23.5–42.1) |
Progression-free survival, months | 13.8 (11.2–20.4) | 36.0 (23.5–40.2) |
Overall survival, months | NE | NE |